NASDAQ$AIXC
AIxCrypto Holdings Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2022.
Qualigen Therapeutics reported a decrease in revenue for Q1 2022, primarily due to the termination of their distribution agreement with Sekisui. The company experienced a net loss of $4.3 million, or $0.12 per share, compared to a net loss of $5.2 million, or $0.19 per share, for the corresponding period in 2021.
- Entered an exclusive worldwide license agreement with UCL Business Ltd to develop QN-302, a G-Quadruplex selective transcription inhibitor.
- Extended and expanded research agreement with the University of Louisville Research Foundation to develop RAS-F platform.
- Returned to fully managing the sales, marketing, and distribution of FastPack® after the expiration of the distribution agreement with Sekisui.
- Signed definitive agreements to acquire a majority stake in NanoSynex, an Antimicrobial Susceptibility Testing (AST) platform.
Headline financials
Revenue & EPS history
Qualigen · Revenue · Quarterly
$722K
Revenue by segment
Qualigen · $700K total across 1 segment · Q1 2022
- Product Sales$700K-50.0%100.0%
Forward guidance
Qualigen anticipates increased sales in future quarters as they will receive 100% of the revenue from FastPack® sales. They are also on track with IND-enabling studies for QN-302 and expect to discuss further progress in this development.
Tailwinds
- Increased sales expected in future quarters due to 100% revenue from FastPack® sales.
- On track with IND-enabling studies for QN-302.
- Potential for NanoSynex platform to make a meaningful impact in the global fight against antibiotic-resistant ‘superbugs’.
- Experienced sales professionals assumed from Sekisui.
- Outlook for future quarters continues to show sales growth.
Headwinds
- No assurance that the closing conditions for the NanoSynex transaction will be satisfied.
- No assurance of maintaining diagnostic sales and marketing engine without interruption following the expiration of the Sekisui agreement.
- No assurance of successfully developing any drugs.
- No assurance that preclinical development will be completed on any projected timeline or will be successful.
- The company's stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-1.6%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-8.3%
Avg return
30 days after
43%
16 / 37 earnings
Positive
+18.8%
Q3 2016
Best reaction
-22.8%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | +10.4% | -3.7% | -13.2% | |
| Q2 2025 | +6.8% | +7.1% | +19.0% | |
| Q1 2025 | +2.0% | -7.0% | -37.4% | |
| Q3 2024 | -12.6% | -6.3% | -6.1% | |
| Q2 2024 | -1.7% | +8.5% | -17.5% | |
| Q1 2024 | +5.7% | +68.7% | +41.6% | |
| Q4 2023 | +1.0% | -15.9% | -29.1% | |
| Q3 2023 | +4.5% | +2.4% | -14.7% | |
| Q2 2023 | +1.0% | +2.9% | -6.4% | |
| Q1 2023 | -5.9% | -3.8% | -5.9% | |
| Q4 2022 | +0.9% | +12.7% | +0.8% | |
| Q3 2022 | -4.5% | -3.2% | -35.5% | |
| Q2 2022 | -0.2% | -3.5% | -23.1% | |
| Q1 2022 | +5.4% | +0.0% | +20.8% | |
| Q4 2021 | -3.2% | -5.5% | -15.3% | |
| Q3 2021 | +0.9% | -6.1% | -9.0% | |
| Q2 2021 | -22.8% | -29.3% | -12.0% | |
| Q1 2021 | +17.6% | +20.3% | +46.4% | |
| Q4 2020 | +5.8% | +1.2% | -17.3% | |
| Q4 2019 | -14.0% | -13.5% | +6.9% | |
| Q3 2019 | -16.6% | -25.3% | -31.5% | |
| Q2 2019 | -1.4% | +4.1% | -64.5% | |
| Q1 2019 | -2.8% | -9.6% | -5.1% | |
| Q4 2018 | +10.0% | +9.4% | -10.7% | |
| Q3 2018 | -12.0% | -12.2% | -17.3% | |
| Q2 2018 | -2.4% | -5.9% | -18.5% | |
| Q1 2018 | +1.1% | +13.1% | +7.4% | |
| Q4 2017 | -4.9% | +2.7% | +9.3% | |
| Q3 2017 | -7.2% | -11.1% | -15.3% | |
| Q2 2017 | -4.4% | -6.7% | -2.5% | |
| Q1 2017 | -1.7% | -4.7% | -8.4% | |
| Q4 2016 | -11.4% | +6.6% | -44.6% | |
| Q3 2016 | +18.8% | +25.0% | +23.1% | |
| Q2 2016 | +1.5% | -2.3% | +4.6% | |
| Q1 2016 | -2.8% | — | — | |
| Q3 2015 | -4.7% | — | — | |
| Q2 2015 | -13.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro